Previous 10 | Next 10 |
Portola Pharmaceuticals ( PTLA ) - The company announced that the European Commission granted conditional Marketing Authorization for Ondexxya (andexanet alfa) to be used in adult patients treated with the Factor Xa inhibitor apixaban or rivaroxaban when reversal of anticoagulation is needed...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The U.S. will send a high-level delegation to Beijing next week as trade negotiatio...
Bristol-Myers Squibb ( BMY ) just held an earnings call . I've been writing a lot about the Celgene ( CELG )/Bristol-Myers deal before it got approved by shareholders of both companies. I've owned it in the Special Situations Report since early 2019. Currently, the deal sits at a 1.8% absolut...
Celgene (NASDAQ: CELG ) has submitted a marketing application Europe seeking approval for luspatercept for the treatment of adult patients with very low to intermediate-risk myelodysplastic syndromes-associated anemia who have ring sideroblasts, require red blood cell (RBC) transfusions an...
Submission to EMA follows Biologics Licensing Application submission to U.S. FDA earlier this month Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that Celgene has submitted a Marketing Authorization Application (MAA) to the European Medici...
Celgene (NASDAQ: CELG ) Q1 results ($M): Revenue: 4,025 (+13.8%); product sales: 4,024 (+14.0%). More news on: Celgene Corporation, Healthcare stocks news, Earnings news and commentary, Read more ...
Celgene (NASDAQ: CELG ): Q1 Non-GAAP EPS of $2.55 beats by $0.10 ; GAAP EPS of $2.14. Revenue of $4.02B (+13.6% Y/Y) beats by $10M . Press Release More news on: Celgene Corporation, Earnings news and commentary, Healthcare stocks news,
- Strong double-digit top- and bottom-line growth across portfolio and geographies - Reaffirming 2019 guidance and 2020 financial targets - Pipeline execution: fedratinib, ozanimod and luspatercept regulatory applications submitted year-to-date - Acquisition by Bristol-Myers ...
News, Short Squeeze, Breakout and More Instantly...
Celgene Corporation Company Name:
CELG Stock Symbol:
NASDAQ Market:
In this clip from "The Pharma & Biotech Show" on Motley Fool Live , recorded on Feb. 2 , Motley Fool contributor Brian Orelli analyzes Gilead 's (NASDAQ: GILD) earnings report and discusses why the biotech giant could see fairly low revenue growth or even see earnings dr...
What coronavirus? Amgen 's (NASDAQ: AMGN) latest set of quarterly figures, delivered Tuesday, showed growth in the company's fundamentals during a challenging time for companies across all economic sectors. The veteran biotech company booked revenue of nearly $6.21 billion in the second qu...
It's scary out there right now for investors, with wild market swings and a lot of negative news coming out of quarterly reports. There is one sector, however, that will survive and likely thrive despite the coronavirus pandemic shutdown -- healthcare. That said, investors shouldn't head for jus...